
Catch up on the top radiology content of the past week.
Senior Editor, Diagnostic Imaging

Catch up on the top radiology content of the past week.

For patients with known or suspected neuroendocrine tumors, the radiopharmaceutical 64Cu-SARTATE offered over 50 percent higher average detection of liver foci than 68Ga-DOTATATE at four hours and 20 hours post-injection, according to research presented at the recent SNMMI conference.

In a recent interview, Amy Patel, MD, discussed recent research on breast cancer screening, pertinent obstacles and keys to facilitating improved adherence with mammography screening.

While acknowledging key limitations, the authors of a new literature review noted that contrast-enhanced mammography offers a viable alternative to conventional imaging and breast MRI for preoperative tumor evaluation and may have a significant impact on surgical management.

The Star RF Electrode and VIVA RF Electrode are reportedly the first devices to garner a specific cleared indication for benign thyroid nodule ablation.

In comparison to the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer, researchers found that the updated 2023 FIGO system had over a 17 percent decrease for substage agreement between pelvic MRI and pathology findings.

The Mammomat B.brilliant’s ClearCEM image reconstruction technique reportedly utilizes advanced algorithms to facilitate improved noise reduction and lesion enhancement.

In recent interviews with Diagnostic Imaging, Jeremie Calais, MD, PhD, Michael Hofman, MBBS, FRACP, Heather Jacene, MD, Phillip Kuo, MD, and more shared their thoughts about the potential impact of theranostics and what excites them about the future of nuclear medicine.

Catch up on the top radiology content of the past week.

Researchers found that non-contrast head CT exams, head and neck CT exams and spine CT imaging increased by 33 percent, 76.9 percent and 52.9 percent, respectively, per 1,000 emergency department encounters over the last decade.

The new functionalities for the AI-enabled Breast Suite software include automated identification of breast arterial calcifications and integration of prior mammograms.

The First Read software provides preliminary drafting of radiology reports based on AI assessment of chest X-rays.

The Oncology Virtual Expert AI software reportedly provides semi-automated segmentation maps of brain tumors based on standard brain MRI scans.

In a recent interview discussing the SNMMI conference, Jeremie Calais, MD, PhD, shared his thoughts on emerging advances. a key mentor in nuclear medicine and combination therapy for prostate cancer.

The newly launched HOPPR Presto Agent reporting platform can be integrated into existing radiology systems and AI models without the need for new software.

In a recent interview, Constance Lehman, MD, PhD, discussed newly published research demonstrating the dynamic capability of AI-based risk scores, drawn from screening mammograms, to facilitate risk-adaptive screening.

In a recent episode of our “Molecular Imaging in Focus” series, Surekha Yadav, MBBS, MD, discussed research presented at the SNMMI conference that showed significant advantages of PSMA PET over conventional imaging for detection of osseous oligometastatic prostate cancer (PCa).

The VascularAssist Occlusion Triage software reportedly demonstrated over a 90 percent sensitivity for detecting peripheral artery disease (PAD) on CT in clinical performance testing.

Catch up on the top radiology content of the past week.

The use of FAPI PET/CT offered a 97 percent pooled sensitivity for detecting peritoneal metastases in a patient-based analysis in a new meta-analysis involving over 800 patients.

For patients with advanced melanoma, the melanin-targeted PET radiotracer (¹⁸F)DMPY2 offered superior detection of metastatic foci in the brain and liver in comparison to (¹⁸F)FDG, according to preliminary comparative research presented at the recent SNMMI conference.

In a recent interview, Mary L. Bouxsein, PhD, discussed challenges with access to dual-energy X-ray absorptiometry (DEXA) screening for osteoporosis, the emergence of biomechanical CT (BCT) and the potential impact of national Medicare coverage of BCT for bone mass measurement.

For pancreatic cancers less than or equal to 20 mm, a deep learning model offered a nearly 45 percent higher sensitivity rate with non-contrast CT in comparison to unassisted radiologist interpretation.

In the latest episode of the Molecular Imaging in Focus series, Michael Hofman, MBBS, FRACP, discussed the potential of an emerging PET radiotracer for DVT detection spotlighted in SNMMI’s “Image of the Year,” a new advance in total body PET/CT and other highlights from the SNMMI conference.

While use of an AI software demonstrated significantly higher accuracy in evaluating BI-RADS 2 presentations and no significant difference with radiologists in BI-RADS 4 assessments of breast ultrasound in a sub-analysis, researchers noted the exclusion of galactoceles, fluid collections and skin lesions that are commonly found in pregnant and lactating women.

In a recent interview, new SNMMI president Heather Jacene, MD, discussed key goals for bolstering workforce development in nuclear medicine, improving infrastructure equity and optimizing emerging advances to facilitate precision treatments in oncology.

Indicated for the detection and visualization of abnormal vascularity in the central nervous system (CNS) and non-CNS body regions, gadoquatrane provides 60 percent less gadolinium dosing in comparison to other macrocyclic gadolinium (Gd)-based contrast agents (mGBCAs).

Catch up on the top radiology content of the past week.

In a recent interview, Nina Kottler, MD, discussed the challenges with traditional radiology reporting, its impact on cognitive load and the recently launched AI-enabled platform Mosaic Reporting.

For men with high clinical risk for prostate cancer (PCa) and a lack of significant findings on mpMRI, triage use of PSMA PET/CT resulted in a 49 percent reduction of biopsies and an 18 percent reduction in detection of clinically insignificant PCa, according to newly published research.